Division of Viral Hepatitis (EIS 2018)

The Division of Viral Hepatitis (DVH), in collaboration with U.S. and global partners, provides the scientific and programmatic foundation and leadership for the prevention and control of viral hepatitis infections and their manifestations. DVH has a broad scope of domestic and global activities, including exciting outbreak investigations; surveillance programs; analytic, cost- effectiveness, vaccination, and behavioral studies; and the prevention and control of blood-borne, enteric, sexual, and chronic diseases.

Areas of emphasis:

• Characterizing the epidemiology of hepatitis C virus infection (HCV), including nosocomial, perinatal, and sexual modes of transmission, along with HCV incidence among persons who inject drugs
• Developing new strategies to prevent HCV virus infection
• Preventing sequelae of chronic hepatitis B and C through early identification and management of cases
• Evaluating the performance of hepatitis A and hepatitis B vaccines and the impact of vaccination programs in the United States and overseas
• Characterizing the epidemiology of hepatitis A
• Evaluating the natural history and spectrum of chronic hepatitis B and C disease, access to care, and beneficial and adverse effects of evolving hepatitis therapy
• Defining morbidity and mortality due to chronic liver disease and liver cancer in the United States
• Addressing global health issues, including determining the burden of chronic liver disease, developing and evaluating strategies to prevent blood-borne infections related to unsafe injection practices, and evaluating strategies to improve hepatitis B vaccination programs in countries in the developing world